Announces Radiomics Collaboration with Moffit Cancer Center

(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has entered into a collaboration agreement with Moffitt Cancer Center to extract radiomics data using their proprietary HealthMyne platform from CT scans of late stage lung cancer patients treated with L-DOS47.

Radiomic features have the potential to uncover disease characteristics that would be otherwise missed during a routine CT or PET scan analysis. These distinctive imaging features may be useful for predicting prognosis and therapeutic response for various conditions. In collaboration with Helix, the Moffitt’s Cancer Imaging and Technology Center of Excellence imaging informatics specialists will build response prediction models using delta radiomics from CT scans of patients treated with L-DOS47 in the LDOS002 Phase I monotherapy study.